Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor XIa inhibitor asundexian (50mg) compared ...
Neuroprotection in ischaemic stroke commonly means a treatment that results in the preservation of brain tissue in the setting of either focal or global ischaemia. The nominal focus on neuronal tissue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results